Sugi Predict

Sugi Predict / Compounds / SCHEMBL224789

SCHEMBL224789

SCHEMBL224789

Nc1ccc(CCCCC(=O)O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.66
▸ RXFP1 Q9HBX9 1/20 0.66
▸ MAOB P27338 3/20 0.61
▸ HDAC3 O15379 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ ADRA1A P35348 1/20 0.59
▸ HDAC4 P56524 1/20 0.59
▸ SLC6A3 Q01959 1/20 0.59
▸ HDAC1 Q13547 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ HDAC7 Q8WUI4 1/20 0.59
▸ HDAC2 Q92769 1/20 0.59
▸ HDAC10 Q969S8 1/20 0.59
▸ HDAC11 Q96DB2 1/20 0.59
▸ HDAC8 Q9BY41 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.59
▸ HDAC9 Q9UKV0 1/20 0.59
▸ HDAC5 Q9UQL6 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.55
▸ FFAR1 O14842 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10987845 0.98 MAPT (0.69) MAPTRXFP1MAOBHDAC3MAPK1
SCHEMBL4423281 0.98 MAPT (0.69) MAPTRXFP1MAOBHDAC3MAPK1
SCHEMBL434792 0.94 SMN1; SMN2 (0.67) MAPTRXFP1MAOBHDAC3MAPK1
SCHEMBL7065645 0.89 MAPT (0.79) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL11760587 0.89 SMN1; SMN2 (0.60) MAPTRXFP1MAOBHDAC3MAPK1
SCHEMBL9329305 0.88 MAPT (0.66) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL9671779 0.87 MAPT (0.83) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL3814880 0.87 MAPT (0.83) MAPTRXFP1HDAC3MAPK1ADRA1A
Adipic Acid SCHEMBL29044502 0.87 LMNA (0.58) MAPTRXFP1HDAC3MAPK1ADRA1A
SCHEMBL7827144 0.85 MAPT (0.80) MAPTRXFP1HDAC3MAPK1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING ILLUMINA, INC. 2023-11-09 — — US disclosed
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING ILLUMINA, INC. 2023-11-09 — — US disclosed
US-11427557-B2 Synergists for quinacridone magenta pigments CABOT CORPORATION (US) 2022-08-30 — — US disclosed
US-20200377470-A1 SYNERGISTS FOR QUINACRIDONE MAGENTA PIGMENTS CABOT CORPORATION 2020-12-03 — — US disclosed
CN-104284891-B Conformationally constrained, fully synthetic macrocyclic compounds 波利弗尔股份公司 2018-04-17 — — CN disclosed
EP-2723724-B1 PIPERAZINE DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN THE TREATMENT OF INSULINORESISTANCE METABOLYS (FR) 2016-11-30 — — EP disclosed
CN-103429269-B Contain with the coupling of polyanion polypeptide, derived from the conjugated molecule that is used for the treatment of AIDS of the peptide of CD4 acceptor INSTITUT PASTEUR (FR) 2016-05-11 — — CN disclosed
US-9045423-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2015-06-02 — — US disclosed
CN-103328460-B glycosyl-CF2-serine and glycosyl-CF2Derivatives of-threonine TFCHEM 2015-03-25 — — CN disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed
CN-103429269-A New conjugated molecules comprising peptide derived from CD4 receptor coupled to polyanionic polypeptide for treatment of AIDS PASTEUR INSTITUT 2013-12-04 — — CN disclosed
CN-103328460-A glycosyl-CF2-serine and glycosyl-CF2Derivatives of-threonine TFCHEM 2013-09-25 — — CN disclosed
CN-101268093-B Age inhibitors PHARMAMENS 2013-04-03 — — CN disclosed
CN-101379044-B Heterobicyclic sulfonamide derivatives for the treatment of diabetes HOFFMANN LA ROCHE 2012-04-11 — — CN disclosed
EP-2415764-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT Kowa Company, Ltd. (JP) 2012-02-08 — — EP disclosed
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2012-01-05 — — US disclosed
CN-101903375-A Carboxyl- or hydroxyl-substituted benzimidazole derivatives HOFFMANN LA ROCHE 2010-12-01 — — CN disclosed
CN-101379044-A Heterobicyclic sulfonamide derivatives for the treatment of diabetes HOFFMANN LA ROCHE (CH) 2009-03-04 — — CN disclosed
CN-101268093-A Age inhibitors PHARMAMENS (FR) 2008-09-17 — — CN disclosed
US-4026896-A ANTIALLERGENS KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) 1977-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377470-A1 SYNERGISTS FOR QUINACRIDONE MAGENTA PIGMENTS RB1, CCNT1, EYA3 MAPT 239/4885RXFP1 3125/4885MAOB 1097/4885
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 MAPT 4876/4885RXFP1 362/4885MAOB 2785/4885
US-20230357307-A1 CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING TENT4A, TENT4B, DNTT MAPT 4102/4885RXFP1 2767/4885MAOB 4799/4885
US-11427557-B2 Synergists for quinacridone magenta pigments RB1, CCNT1, EYA3 MAPT 239/4885RXFP1 3125/4885MAOB 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.